

# UC Davis

## UC Davis Previously Published Works

### Title

Hydrophilic Interaction Liquid Chromatography-Hydrogen/Deuterium Exchange-Mass Spectrometry (HILIC-HDX-MS) for Untargeted Metabolomics.

### Permalink

<https://escholarship.org/uc/item/51s9q33h>

### Journal

International Journal of Molecular Sciences, 25(5)

### Authors

Cajka, Tomas

Hricko, Jiri

Rakusanova, Stanislava

et al.

### Publication Date

2024-03-01

### DOI

10.3390/ijms25052899

Peer reviewed



Article

# Hydrophilic Interaction Liquid Chromatography–Hydrogen/Deuterium Exchange–Mass Spectrometry (HILIC-HDX-MS) for Untargeted Metabolomics

Tomas Cajka <sup>1,\*</sup>, Jiri Hricko <sup>1</sup>, Stanislava Rakusanova <sup>1</sup>, Kristyna Brejchova <sup>1</sup>, Michaela Novakova <sup>1</sup>, Lucie Rudl Kulhava <sup>1</sup>, Veronika Hola <sup>1</sup>, Michaela Paucova <sup>1</sup>, Oliver Fiehn <sup>2</sup> and Ondrej Kuda <sup>1</sup>

<sup>1</sup> Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czech Republic; jiri.hricko@fgu.cas.cz (J.H.); stanislava.rakusanova@fgu.cas.cz (S.R.); kristyna.brejchova@fgu.cas.cz (K.B.); michaela.novakova@fgu.cas.cz (M.N.); lucie.kulhava@fgu.cas.cz (L.R.K.); veronika.hola@fgu.cas.cz (V.H.); michaela.paucova@fgu.cas.cz (M.P.); ondrej.kuda@fgu.cas.cz (O.K.)

<sup>2</sup> West Coast Metabolomics Center, University of California, Davis, 451 Health Sciences Drive, Davis, CA 95616, USA; ofiehn@ucdavis.edu

\* Correspondence: tomas.cajka@fgu.cas.cz

**Abstract:** Liquid chromatography with mass spectrometry (LC-MS)-based metabolomics detects thousands of molecular features (retention time– $m/z$  pairs) in biological samples per analysis, yet the metabolite annotation rate remains low, with 90% of signals classified as unknowns. To enhance the metabolite annotation rates, researchers employ tandem mass spectral libraries and challenging in silico fragmentation software. Hydrogen/deuterium exchange mass spectrometry (HDX-MS) may offer an additional layer of structural information in untargeted metabolomics, especially for identifying specific unidentified metabolites that are revealed to be statistically significant. Here, we investigate the potential of hydrophilic interaction liquid chromatography (HILIC)-HDX-MS in untargeted metabolomics. Specifically, we evaluate the effectiveness of two approaches using hypothetical targets: the post-column addition of deuterium oxide ( $D_2O$ ) and the on-column HILIC-HDX-MS method. To illustrate the practical application of HILIC-HDX-MS, we apply this methodology using the in silico fragmentation software MS-FINDER to an unknown compound detected in various biological samples, including plasma, serum, tissues, and feces during HILIC-MS profiling, subsequently identified as  $N^1$ -acetylspermidine.

**Keywords:** metabolomics; liquid chromatography; mass spectrometry; hydrogen/deuterium exchange; unknown identification



**Citation:** Cajka, T.; Hricko, J.; Rakusanova, S.; Brejchova, K.; Novakova, M.; Rudl Kulhava, L.; Hola, V.; Paucova, M.; Fiehn, O.; Kuda, O. Hydrophilic Interaction Liquid Chromatography–Hydrogen/Deuterium Exchange–Mass Spectrometry (HILIC-HDX-MS) for Untargeted Metabolomics. *Int. J. Mol. Sci.* **2024**, *25*, 2899. <https://doi.org/10.3390/ijms25052899>

Academic Editor: Eleni Bairaktari

Received: 15 January 2024

Revised: 17 February 2024

Accepted: 26 February 2024

Published: 1 March 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Metabolomics studies low-molecular-weight compounds, typically <2000 Da, within complex biological systems under specific conditions [1]. For the analysis of polar metabolites, liquid chromatography with mass spectrometry (LC-MS), specifically reversed-phase liquid chromatography (RPLC) and hydrophilic interaction liquid chromatography (HILIC), serves as the primary separation technique [2], followed by gas chromatography (GC) [3] and capillary electrophoresis (CE) [4,5]. Overall, LC-MS has become the most applied chromatography–MS tool for analyzing polar and nonpolar metabolites such as lipids [4]. Indeed, a combination of multiple chromatography–MS-based platforms has become a common approach to achieving wide metabolome and lipidome coverage [6–9].

LC-MS-based metabolomics can generate thousands of molecular features/ion peaks (i.e., retention time– $m/z$  pairs) in biological samples per single analysis. However, it is estimated that only 10% of these features can be annotated according to mass spectra library matches [10,11], leaving the remaining 90% as unknowns. Thus, metabolomics faces a low identification rate [12] despite the overcounting of features that either do not

trigger the accompanying MS/MS spectra or need to be accounted for differently due to adducts [13,14]. Untargeted metabolomics studies often provide only sets of annotated metabolites, unknowns are not further investigated because additional resources are needed, and the structure elucidation process is time-consuming. However, studies focused, for instance, on circadian rhythms [12,15], cardiovascular diseases [16], type 2 diabetes [17], lung cancer [18], or nutrition [19] have shown that these unknowns can be statistically significant, and focus on their structure elucidation may bring valuable insights into metabolic pathways, potentially uncovering novel biomarkers or therapeutic targets associated with these specific physiological and pathological conditions [20].

The metabolite annotation rate can be increased by collecting information from the MS analysis of certified standards and making these data publicly accessible in mass spectral repositories [21,22]. However, acquiring the MS/MS spectra of all authentic metabolites in every laboratory is unrealistic. As a more viable solution, tandem mass spectral libraries were developed to annotate the MS/MS spectra obtained during metabolomics experiments. Despite the availability of various commercial and public MS/MS libraries such as NIST 23, METLIN Gen2, MassBank, and MoNA [21,23,24], many false positive annotations may be reported [9,25,26].

Employing computational simulations to predict the mass spectra from input structures can further increase the annotation rate [27]. Various existing *in silico* fragmentation software programs, including Mass Frontier, CSI:FingerID, CFM-ID, MS-FINDER, MIDAS-G, and MetFrag [27–32], are utilized for identifying unknown metabolites and determining their chemical structures. Typically, these tools convert mass data into molecular fragments using combinatorial structure generation techniques with limited success. Hence, it is crucial to integrate additional orthogonal information to determine the correct structure. Such methods may be used to annotate unknown compounds while also reducing false positive annotations originating from MS/MS search and *in silico* fragmentation software. Hydrogen/deuterium exchange mass spectrometry (HDX-MS), a well-established technique in proteomics and for the structural elucidation of pharmaceutical impurities and drug metabolites, though not fully explored in metabolomics, provides a promising approach [33–43].

Exchangeable hydrogen atoms (also called active, acidic, or labile), bound to heteroatoms such as oxygen, nitrogen, and sulfur, readily exchange with deuterium, while those bound to carbon remain unaltered [44]. When metabolites are exposed to deuterium oxide (D<sub>2</sub>O), labile hydrogens within various functional groups such as –NH–, –NH<sub>2</sub>, –OH, –COOH, and –SH are substituted with deuterium. Using a mass spectrometer, the number of replaced hydrogens in the molecule can be determined by measuring the molecular mass before and after HDX. Such information can be a valuable filter, narrowing down potential candidates for structure elucidation [45,46].

Notably, HDX-MS has been successfully used to identify compounds like *N,N,N*-trimethyl-L-alanyl-L-proline betaine [47] and (2*R*,3*R*)-2,3-dihydroxy-5-methylthio-4-pentenoic acid [48] in human plasma, endogenous carbonyl steroids in human serum [49], complex lipids in mouse brains [50], secondary metabolites in root exudates of *Arabidopsis thaliana* [51], and *N*-methyl lysophosphatidylethanolamines as abundant lipids in acidophilic mixed microbial communities [34]. However, these studies did not extensively cover the development and overall performance of the HDX approach.


Here, we evaluate the potential of LC-HDX-MS in untargeted metabolomics. Specifically, we compare the performance of two methods: the post-column addition of D<sub>2</sub>O and the on-column HILIC-HDX-MS method. In the latter case, we also evaluate variations when only water is replaced with D<sub>2</sub>O and non-deuterated mobile-phase modifiers are used (partial HILIC-HDX-MS) or both D<sub>2</sub>O and deuterated mobile-phase modifiers are used (full HILIC-HDX-MS). We exemplify this approach by identifying an unknown metabolite detected in various biological samples (biofluids, tissues, feces) of rats, mice, and humans.

## 2. Results and Discussion

Untargeted metabolomics and lipidomics studies typically report hundreds of annotated metabolites, usually after combining data from various LC-MS platforms. However, many more metabolites remain unidentified. Elemental formulas can be correctly assigned in 95% of all unknowns [9], but annotating these compounds is challenging. Chemical transformations such as HDX may reveal substructure information and be used to discard false positive isomer structures from chemical database queries to differentiate lists of possible isomers.

For this evaluation, we adapted our fast HILIC-MS method [52], utilizing an ACQUITY Premier BEH Amide column (50 mm × 2.1 mm i.d.; 1.7 μm particle size) equipped with a VanGuard FIT cartridge (5 mm × 2.1 mm i.d.; 1.7 μm particle size) and employing an 8.5 min injection-to-injection time. The HILIC-MS method uses acetonitrile/water (95:5) and water as mobile phases, both with ammonium formate (10 mM) and formic acid (0.125%) (Table 1).

Considering the simplicity of operation, we initially focused on evaluating the performance of the standard HILIC-MS profiling method, modified only with the post-column addition of D<sub>2</sub>O. In this case, the previously injected extracts in an acetonitrile/water (4:1, *v/v*) mixture were subsequently analyzed using the same HILIC-MS method but with a post-column addition of D<sub>2</sub>O introduced using an infusion pump (Figure 1, Table 1). The advantage of this approach is that no further modification of the mobile phases and resuspended extracts was needed.



**Figure 1.** Experimental design of LC-HDX-MS experiments: setup (1) of conventional HILIC-MS method with a post-column addition of D<sub>2</sub>O, setup (2) of partial on-column LC-HDX-MS method, and setup (3) of full on-column LC-HDX-MS method. ACN, acetonitrile; AmF, ammonium formate; FA, formic acid.

Next, we turned our attention to on-column HILIC-HDX-MS methods with modified mobile phases and the resuspension of dry extracts. For partial HILIC-HDX-MS, only water was replaced by D<sub>2</sub>O, and non-deuterated mobile-phase modifiers (ammonium formate and formic acid) were used. The dry extracts were resuspended in an acetonitrile/D<sub>2</sub>O (4:1, *v/v*) mixture. The advantage of this approach is that only the key H/D exchange solvent (D<sub>2</sub>O) was needed. On the other hand, for full HILIC-HDX-MS, both D<sub>2</sub>O and deuterated mobile-phase modifiers (D<sub>5</sub>-ammonium formate and D<sub>2</sub>-formic acid) were employed, and the dry extracts were again resuspended in an acetonitrile/D<sub>2</sub>O (4:1, *v/v*) mixture (Figure 1, Table 1). All the H/D exchange components were replaced in this last tested method, thus requiring more individual D-labeled chemicals during the run.

**Table 1.** Overview of the key characteristics of evaluated HILIC-MS methods.

Specification	HILIC-MS	HILIC-MS with D <sub>2</sub> O Co-Infusion	Partial HILIC-HDX-MS	Full HILIC-HDX-MS
Mobile Phase A	H <sub>2</sub> O 10 mM Ammonium Formate 0.125% Formic Acid	H <sub>2</sub> O 10 mM Ammonium Formate 0.125% Formic Acid	D <sub>2</sub> O 10 mM Ammonium Formate 0.125% Formic Acid	D <sub>2</sub> O 10 mM D <sub>5</sub> -Ammonium Formate 0.125% D <sub>2</sub> -Formic Acid
Mobile Phase B	95% Acetonitrile/5% H <sub>2</sub> O 10 mM Ammonium Formate 0.125% Formic Acid	95% Acetonitrile/5% H <sub>2</sub> O 10 mM Ammonium Formate 0.125% Formic Acid	95% Acetonitrile/5% D <sub>2</sub> O 7.5 mM Ammonium Formate 0.125% Formic Acid	95% Acetonitrile/5% D <sub>2</sub> O 7.5 mM D <sub>5</sub> -Ammonium Formate 0.125% D <sub>2</sub> -Formic Acid
Resuspension Solvent	Acetonitrile/H <sub>2</sub> O (4:1, <i>v/v</i> ) with CUDA, Val-Tyr-Val (IS)	Acetonitrile/H <sub>2</sub> O (4:1, <i>v/v</i> ) with CUDA, Val-Tyr-Val (IS)	Acetonitrile/D <sub>2</sub> O (4:1, <i>v/v</i> ) with CUDA, Val-Tyr-Val (IS)	Acetonitrile/D <sub>2</sub> O (4:1, <i>v/v</i> ) with CUDA, Val-Tyr-Val (IS)
Column Flow Rate	0.4 mL/min	0.4 mL/min	0.4 mL/min	0.4 mL/min
Co-Infusion Solvent	—	D <sub>2</sub> O	—	—
Co-Infusion Flow Rate	—	0.05, 0.1 mL/min	—	—

### 2.1. HILIC-MS with the Post-Column Addition of D<sub>2</sub>O

For the first setup, we used the post-column addition of D<sub>2</sub>O introduced via a Tee connector into the LC effluent using an infusion pump. We first evaluated this approach for a range of polar metabolites with varying numbers of exchangeable hydrogen atoms. For these hypothetical targets, we assessed the extent of H/D exchange. As Figure 2a shows, the post-column co-infusion of D<sub>2</sub>O at a flow rate of 50 µL/min against a HILIC column flow of 400 µL/min led to the detection of the molecules as [M+D]<sup>+</sup> ions as base peaks (100%), and only limited H/D exchange occurred. A slight improvement was observed with the increased addition of D<sub>2</sub>O (100 µL/min), leading to the detection of base peaks for [M(D<sub>1</sub>)+D]<sup>+</sup> ions with one H/D exchange (Figure 2b). We also included in Figure 2 an internal standard, 12-[[cyclohexylamino]carbonyl]amino]-dodecanoic acid (CUDA), eluting at 0.45 min, in which case the co-infusion of D<sub>2</sub>O led to complete H/D exchange ([M(D<sub>3</sub>)+D]<sup>+</sup>). This can be explained by the low content of H<sub>2</sub>O (Figure 3a) in the mobile phase with co-infused D<sub>2</sub>O (~83% D<sub>2</sub>O, Figure 3b).

However, most polar metabolites were eluted during HILIC-MS at the composition of the mobile phases, favoring a high content of H<sub>2</sub>O (3–5 min); thus, the content of co-infused D<sub>2</sub>O (100 µL/min) is reduced to 25–40% compared to H<sub>2</sub>O from the mobile phases (Figure 3b). This shortcoming led to the incomplete H/D exchange mass spectra of the evaluated polar metabolites, which would be difficult to interpret if these were unknowns. Shah et al. [37] showed with the example of drug metabolites that the post-column addition of D<sub>2</sub>O was efficient when the LC output was 50 µL/min and a D<sub>2</sub>O infusion rate of 126 µL/min (~1:2.5 ratio) was used. However, splitting the LC flow was required, possibly leading to a signal reduction and requiring further modification of the LC-MS setup. Of note, resuspending the samples in an acetonitrile/D<sub>2</sub>O (4:1, v/v) mixture with follow-up analysis did not improve the H/D exchange. Thus, the post-column addition of D<sub>2</sub>O appeared to provide limited potential for H/D exchange, as also highlighted by Liu et al. [33] during pharmaceutical compound analysis.

### 2.2. Partial and Full HILIC-HDX-MS

In the subsequent two setups of on-column HILIC-HDX-MS, we replaced H<sub>2</sub>O with D<sub>2</sub>O as the component of both mobile phases but kept unlabeled mobile-phase modifiers (ammonium formate, formic acid), i.e., partial HILIC-HDX-MS, or also replaced the mobile-phase modifiers with deuterated counterparts (D<sub>5</sub>-ammonium formate, D<sub>2</sub>-formic acid), i.e., full HILIC-HDX-MS.

However, for mobile phase B containing acetonitrile and D<sub>2</sub>O (95:5, v/v), we observed solubility issues with both 10 mM ammonium formate and 10 mM D<sub>5</sub>-ammonium formate compared to the acetonitrile/H<sub>2</sub>O (95:5, v/v) mixture with 10 mM ammonium formate. Based on our experience, the light turbidity disappears after sonication when preparing fully non-labeled mobile phase B. However, this was not the case when D<sub>2</sub>O was used instead of H<sub>2</sub>O. For complete dissolving of the salts, sonication at 25 °C for 10 mM ammonium formate or even 30 °C for the D<sub>5</sub>-ammonium formate solutions was needed.

Unfortunately, after cooling both solutions to lab temperature (23 °C), we observed crystals of the salts, although the solutions were not turbid. We found that 7.5 mM of ammonium formate or D<sub>5</sub>-ammonium formate was a limiting concentration when D<sub>2</sub>O was used as a part of mobile phase B. However, this modification of mobile phase B did not impact the metabolites' retention time shift or peak shape.

**(a) HILIC-MS with D<sub>2</sub>O Co-Infusion (50 μL/min)**

Metabolite	#H Bond Donors	[M+H] <sup>+</sup> [M+D] <sup>+</sup>		[M(D <sub>x</sub> )+D] <sup>+</sup>							Ion Abundance (%)	
				D <sub>1</sub>	D <sub>2</sub>	D <sub>3</sub>	D <sub>4</sub>	D <sub>5</sub>	D <sub>6</sub>	D <sub>7</sub>		
CUDA (IS)	3	3	19	63	100	60						
Proline	2	63	100	57	9							
Phenylalanine	3	39	100	99	43	7						
Leucine	3	44	100	98	42	6						
Glycine	3	52	100	82	29	4						
Glutamate	4	45	100	89	37	9	0					
Threonine	4	39	99	100	52	13	1					
Histidine	4	51	100	80	31	6	0					
Lysine	5	46	100	90	44	11	2	0				
Arginine	7	46	100	100	56	21	5	1	0	0		

**(b) HILIC-MS with D<sub>2</sub>O Co-Infusion (100 μL/min)**

Metabolite	#H Bond Donors	[M+H] <sup>+</sup> [M+D] <sup>+</sup>		[M(D <sub>x</sub> )+D] <sup>+</sup>							Ion Abundance (%)	
				D <sub>1</sub>	D <sub>2</sub>	D <sub>3</sub>	D <sub>4</sub>	D <sub>5</sub>	D <sub>6</sub>	D <sub>7</sub>		
CUDA (IS)	3		6	35	89	100						
Proline	2	31	92	100	34							
Phenylalanine	3	9	50	100	91	30						
Leucine	3	10	49	100	87	29						
Glycine	3	15	65	100	74	21						
Glutamate	4	9	55	100	91	36	6					
Threonine	4	10	48	99	100	53	9					
Histidine	4	17	63	100	77	31	5					
Lysine	5	13	53	100	97	52	15	2				
Arginine	7	19	65	100	88	51	21	6	1	0		

**(c) Partial HILIC-HDX-MS**


Metabolite	#H Bond Donors	[M+H] <sup>+</sup> [M+D] <sup>+</sup>		[M(D <sub>x</sub> )+D] <sup>+</sup>							Ion Abundance (%)	
				D <sub>1</sub>	D <sub>2</sub>	D <sub>3</sub>	D <sub>4</sub>	D <sub>5</sub>	D <sub>6</sub>	D <sub>7</sub>		
CUDA (IS)	3		4	26	79	100						
Proline	2		2	21	100							
Phenylalanine	3			5	37	100						
Leucine	3			5	37	100						
Glycine	3			2	27	100						
Glutamate	4				4	28	100					
Threonine	4				5	33	100					
Histidine	4			1	8	39	100					
Lysine	5				1	9	46	100				
Arginine	7							3	22	100		

**(d) Full HILIC-HDX-MS**

Metabolite	#H Bond Donors	[M+H] <sup>+</sup> [M+D] <sup>+</sup>		[M(D <sub>x</sub> )+D] <sup>+</sup>							Ion Abundance (%)	
				D <sub>1</sub>	D <sub>2</sub>	D <sub>3</sub>	D <sub>4</sub>	D <sub>5</sub>	D <sub>6</sub>	D <sub>7</sub>		
CUDA (IS)	3		1	13	59	100						
Proline	2		1	16	100							
Phenylalanine	3			3	29	100						
Leucine	3			3	26	100						
Glycine	3			1	18	100						
Glutamate	4			1	3	23	100					
Threonine	4				2	23	100					
Histidine	4			1	4	26	100					
Lysine	5					4	29	100				
Arginine	7							1	15	100		

**Figure 2.** Evaluation of selected target compounds containing 2–7 labile hydrogens (#H Bond Donors) under (a) conventional HILIC-MS with post-column addition of D<sub>2</sub>O (50 μL/min); (b) conventional HILIC-MS with post-column addition of D<sub>2</sub>O (100 μL/min); (c) partial HILIC-HDX-MS with D<sub>2</sub>O used in the mobile phases; (d) full HILIC-HDX-MS with D<sub>2</sub>O, D<sub>5</sub>-ammonium formate, D<sub>2</sub>-formic acid used in the mobile phases. Full H/D exchange is indicated with a solid box (□). The most abundant ion (base peak) in the MS1 spectrum is labeled blue (■), and the color of lower intensities is proportionally scaled. For details of the composition of mobile phases and used modifiers, see Table 1.





**Figure 3.** (a) Total flow of  $\text{H}_2\text{O}$  and acetonitrile (ACN) from mobile phase A ( $\text{H}_2\text{O}$ ) and mobile phase B (acetonitrile/ $\text{H}_2\text{O}$  95:5) and post-column addition of  $\text{D}_2\text{O}$  (100  $\mu\text{L}/\text{min}$ ). (b) Ratio of  $\text{D}_2\text{O}/(\text{D}_2\text{O}+\text{H}_2\text{O})$  when co-infusing  $\text{D}_2\text{O}$  (100  $\mu\text{L}/\text{min}$ ) during the HILIC method (400  $\mu\text{L}/\text{min}$ ).


Figure 2c,d show that the partial and full HILIC-HDX-MS setups provided complete H/D exchange for the evaluated metabolites compared to the setup with the post-column addition of  $\text{D}_2\text{O}$ . The full HILIC-HDX-MS method demonstrated slightly better performance, as the intensities of the  $[\text{M}(\text{D}_{x-1})+\text{D}]^+$  ions were lower (with an average absolute difference of  $\sim 10\%$ ) compared to the  $[\text{M}(\text{D}_x)+\text{D}]^+$  ions, which represent the full H/D exchange species with  $x$  deuterium atoms. The increased ratio of  $[\text{M}(\text{D}_{x-1})+\text{D}]^+ / [\text{M}(\text{D}_x)+\text{D}]^+$  ions in the partial HILIC-HDX-MS method can be attributed to the presence of non-deuterated mobile-phase modifiers providing hydrogen atoms, thereby reducing the yield of fully deuterated ions.

We should also note that the H/D exchange efficiency has been reported to be pH-dependent [53]. For example, amides demonstrate a minimum exchange rate around a pH of 2.5 [54], while carbohydrates, primarily composed of hydroxyls, exhibit a minimum exchange rate around a pH of 6.5, with the exchange rate increasing as the solution becomes more acidic or basic [55]. The pH of the mobile phases used in the HILIC method was approximately 3, aligning with the observed pH-dependent trends in amides and carbohydrates. However, as metabolomic profiling encompasses diverse groups of metabolites, the H/D exchange efficiency can vary based on the pH of the mobile phase.

Figure 4 shows an example of the amino acid lysine with five labile hydrogen atoms acquired using conventional HILIC-MS with detected  $[\text{M}+\text{H}]^+$  ions (Figure 4a), followed by incomplete H/D exchange when using the post-column addition of  $\text{D}_2\text{O}$ , providing ions from  $[\text{M}+\text{H}]^+$  to  $[\text{M}(\text{D}_5)+\text{D}]^+$  (Figure 4b), and complete H/D exchange when the full HILIC-HDX-MS method was used, with dominating  $[\text{M}(\text{D}_5)+\text{D}]^+$  ions (Figure 4c). All these data show that on-column H/D exchange is advantageous since it generally produces



a high yield of fully deuterated compounds owing to the adequate mixing time of the metabolites with the deuterated mobile phases.



**Figure 4.** MS1 spectra of amino acid lysine obtained using (a) conventional HILIC-MS ( $m/z$  147.1128,  $[M+H]^+$ ), (b) conventional HILIC-MS with post-column addition of D<sub>2</sub>O (100  $\mu$ L/min), and (c) full HILIC-HDX-MS ( $m/z$  153.15046,  $[M(D_5)+D]^+$ ). The lysine structure indicates the molecule's possible exchangeable hydrogens (in red).

Regarding D<sub>2</sub>O consumption, 850  $\mu$ L of D<sub>2</sub>O per injection was necessary when utilizing the post-column addition of D<sub>2</sub>O (100  $\mu$ L/min), whereas approximately 600  $\mu$ L of mobile phase A with D<sub>2</sub>O and 2.8 mL of mobile phase B (including  $\sim$ 140  $\mu$ L D<sub>2</sub>O) was required for the partial or full HILIC-HDX-MS setups. Thus, both approaches involved comparable volumes of D<sub>2</sub>O. However, the partial or full HILIC-HDX-MS setups provided more efficient deuterium incorporation into the analytes, making them the preferred choice for achieving complete H/D exchange in untargeted metabolomics studies.

### 2.3. Structure Elucidation of N<sup>1</sup>-Acetylspermidine Using HILIC-HDX-MS


When processing raw HILIC-MS files from multiple studies focused on nutritional intervention [56], circadian rhythms [57], drug treatment [58], or heart failure [59], we have repeatedly observed an unknown metabolite eluted at a retention time of 4.3 min and  $m/z$  188.1757 in various biological matrices (biofluids, tissues, feces) of rats, mice, and humans (Figure S1).

Since we did not obtain a positive spectral match when using the combined NIST 23 and MoNA MS/MS libraries, we submitted MS1 isotopic ions and the MS/MS spectrum from MS-DIAL to the MS-FINDER software [27] for structure elucidation. Only one formula (C<sub>9</sub>H<sub>21</sub>N<sub>3</sub>O), within a mass error of <0.005 Da (set up as a criterion for mass tolerance), was reported.


This formula provided the source to 23 local databases in MS-FINDER with 101 possible unique structures. Focusing on such a high number of potential candidates would be

impractical; thus, we applied an additional filter from the HILIC-HDX-MS experiment. Specifically, we obtained information based on the isotopic ions from the conventional HILIC-MS used for polar metabolite profiling and full HILIC-HDX-MS that four labile hydrogens were present in the molecule. Using this information, we reduced the number of potential candidates to 22; thus, 78% of false positive structures were filtered out with this additional filter.

Based on this information and using the two most scored candidates, we analyzed the standards of  $N^1$ -acetylspermidine and  $N^8$ -acetylspermidine using HILIC-MS and HILIC-HDX-MS. Figure 5 shows that the  $N^1$ -acetylspermidine detected in mouse feces matched the standard, including the retention time and MS1 and MS/MS spectra from HILIC-MS and HILIC-HDX-MS after H/D exchange. A similar observation was also confirmed for rat feces (Figure S2) and human plasma NIST SRM 1950 (Figure S3). Figure 6 also shows the MS/MS fragmentation of  $N^1$ -acetylspermidine under HILIC-MS and full HILIC-HDX-MS conditions, further confirming the identity of this unknown metabolite based on H/D exchange in a series of MS/MS fragments. Of note, the standard of  $N^8$ -acetylspermidine provided a longer retention time (0.05 min shift) than the peak of  $N^1$ -acetylspermidine detected in mouse feces, and the MS/MS spectrum did not match (Figure S4). The MS/MS spectra of  $N^1$ -acetylspermidine and  $N^8$ -acetylspermidine can be downloaded in a mass searchable format (MSP) for storing MS/MS spectra ( $m/z$  and intensity of mass peaks) from the Supplementary Materials.




**Figure 5.** Extracted ion chromatograms (EICs) and MS1 and MS/MS spectra of  $N^1$ -acetylspermidine in mouse feces and analytical standard analysis under conventional HILIC-MS and full HILIC-HDX-MS conditions. In HILIC-MS, the EIC at  $m/z$  188.1757, corresponding to  $[M(H_4)+H]^+$ , is displayed. Conversely, in HILIC-HDX-MS, the EIC at  $m/z$  193.2071, corresponding to  $[M(D_4)+D]^+$ , is shown. MS/MS spectra were acquired at stepped normalized collision energies of 20, 30, and 40%.



**Figure 6.** MS/MS fragmentation of  $N^1$ -acetylspermidine under (a) HILIC-MS (precursor ion  $m/z$  188.1757,  $[M(H_4)+H]^+$ ) and (b) full HILIC-HDX-MS (precursor ion  $m/z$  193.2071,  $[M(D_4)+D]^+$ ) conditions.

In addition,  $N^1$ -acetylspermidine appeared statistically significant during our experiments investigating the impact of diet and antibiotic treatment on mice. As Figure 7 shows, there was no statistical difference between the groups of mouse feces under normal (chow) and high-fat diets. On the other hand, after antibiotic treatment, over one order of magnitude difference in signal intensity was observed between these two groups. Interestingly, in mice on a chow diet, the level of  $N^1$ -acetylspermidine decreased 3.8-fold after antibiotics treatment, while on a high-fat diet, the opposite trend was observed (4.1-fold increase), indicating differences in the polyamine pathway of the microbiota.



**Figure 7.** Box plots of  $N^1$ -acetylspermidine during experiments investigating the impact of diet (chow vs. high-fat diet) and antibiotic (ABX) treatment on mice. For statistical analysis, two-way ANOVA was used.

### 3. Materials and Methods

#### 3.1. Materials and Reagents

For the sample extraction, methanol (J.T.Baker, Phillipsburg, NJ, USA, catalog no. 9822), methyl *tert*-butyl ether (Honeywell, Charlotte, NC, USA, catalog no. 34875), and water (VWR, Suwanee, GA, USA, catalog no. 83645.320) were used. The LC-MS-grade solvents for mobile phases included acetonitrile (Honeywell, catalog no. 34967) and water (VWR, catalog no. 83645.320). Mobile-phase modifiers such as ammonium formate (Supelco, Bellefonte, PA, USA, catalog no. 70221) and formic acid (VWR, catalog no. 84865.260) were also of LC-MS-grade quality. The deuterium oxide (catalog no. 617385) and D<sub>5</sub>-ammonium formate (catalog no. 795119) were from Merck, Rahway, NJ, USA. The D<sub>2</sub>-formic acid (catalog no. DLM-286-PK) was from Cambridge Isotope Laboratories, Tewksbury, MA, USA. The N<sup>1</sup>-acetylspermidine (catalog no. 9001535; InChI Key: MQTAVJHICJWXBR-UHFFFAOYSA-N) and N<sup>8</sup>-acetylspermidine (catalog no. 37434; InChI Key: FONIWJIDLJEJTL-UHFFFAOYSA-N) were from Cayman Chemical, Tallinn, Estonia.

The mouse and rat feces samples were from the Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic. The human serum (catalog no. S7023-100ML), NIST SRM 1950 plasma (catalog no. NIST1950), and a mixture of 17 amino acids (catalog no. 79248) were from Merck.

#### 3.2. Experiments with Animals

The age-matched 6-week-old male C57BL/6J mice were from Charles River Laboratories (Sulzfeld, Germany). After their arrival, the mice were individually housed in cages and maintained at 22 °C and according to a 12 h light/dark cycle (light from 6:00 a.m.). The mice were maintained on a chow or high-fat diet (ssniff Spezialdiäten, Soest, Germany) *ad libitum*. The chow diet contained 16% calories from fat, 27% from protein, and 57% from carbohydrates. The high-fat diet contained 60% calories from fat, 20% from protein, and 20% from carbohydrates. One group of mice was on a chow diet ( $n = 16$ ) for three weeks prior to the subsequent experiments, while the other group of mice ( $n = 16$ ) was first on a chow diet for one week (acclimatization), followed by two weeks on a high-fat diet. After these initial periods, each group was split into (i) a control group (no antibiotics) ( $n = 8$ ) and (ii) a treatment group (with antibiotics) ( $n = 8$ ) for two weeks. Ampicillin, streptomycin, and clindamycin at a ratio of 1:1:1 were provided in sterile drinking water at a final concentration of 1 g/L. These antibiotics were chosen due to their broad spectrum capacity and well-documented impacts on the intestinal microbiota [60]. The animals were allowed to drink *ad libitum* during the experiment, with water replacement at 3-day intervals. Feces samples were collected and stored at  $-80$  °C until further analysis.

#### 3.3. Sample Preparation

The metabolites were extracted using a biphasic solvent system of cold methanol, methyl *tert*-butyl ether, and water [52,61].

For the extraction of biofluids (plasma, serum), a 25  $\mu$ L aliquot in a 1.5 mL tube was shaken (30 s) with 165  $\mu$ L ice-cold methanol and 600  $\mu$ L MTBE, both containing internal standards [61]. Subsequently, 165  $\mu$ L of 10% methanol with internal standards [61] was added, vortexed (10 s), and then centrifuged ( $24,328 \times g$ , 5 min, 4 °C). A 70  $\mu$ L aliquot of the bottom phase was collected and evaporated. The dry extracts were resuspended in 70  $\mu$ L of an acetonitrile/water (4:1) or acetonitrile/D<sub>2</sub>O (4:1) mixture with two internal standards (CUDA and Val-Tyr-Val) based on the experimental setup tested (see Table 1). After shaking (30 s), the samples were centrifuged ( $24,328 \times g$ , 5 min, 4 °C) and analyzed using the HILIC metabolomics platform [52].

For the extraction of tissues and feces, 20 mg of the sample in a 2 mL tube was homogenized (1.5 min) with 275  $\mu$ L of methanol using a grinder. Subsequently, 1 mL of MTBE was added, and this mixture was shaken (30 s). Finally, 275  $\mu$ L of 10% methanol was added, and after vortexing (10 s), the tubes were centrifuged ( $24,328 \times g$ , 5 min, 4 °C) [61].

A 70  $\mu$ L aliquot of the bottom phase was collected and evaporated. The dry extracts were further processed as described for biofluids.

### 3.4. LC-MS Conditions

The LC-MS system comprised a Vanquish UHPLC system (Thermo Fisher Scientific, Bremen, Germany) and a Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) equipped with a heated electrospray ionization (HESI-II) probe (Thermo Fisher Scientific), [52,61].

The ACQUITY Premier BEH Amide column (50 mm  $\times$  2.1 mm i.d.; 1.7  $\mu$ m particle size) equipped with a VanGuard FIT cartridge (5 mm  $\times$  2.1 mm i.d.; 1.7  $\mu$ m particle size) (Waters, Milford, MA, USA) was used to separate the polar metabolites. The column was maintained at 45  $^{\circ}$ C. The composition of the mobile phases, resuspension solvent, and column flow rate are summarized in Table 1. Separation was conducted under the following gradient: 0 min 100% (B); 0–1 min 100% (B); 1–3.9 min from 100% to 70% (B); 3.9–5.1 min from 70% to 30% (B); 5.1–6.4 min from 30% to 100% (B); 6.4–7.5 min 100% (B) +1 min pre-injection steps. An injection volume of 1  $\mu$ L was used. The sample temperature was maintained at 4  $^{\circ}$ C.

The ESI source and MS settings were as follows: sheath gas pressure, 50 arbitrary units; aux gas flow, 13 arbitrary units; sweep gas flow, 3 arbitrary units; capillary temperature, 260  $^{\circ}$ C; aux gas heater temperature, 425  $^{\circ}$ C; spray voltage, 3.6 kV; polarity, positive; MS1 mass range,  $m/z$  60–900; MS1 resolving power, 35,000 FWHM; the number of data-dependent scans per cycle, 3; MS/MS resolving power, 17,500 FWHM; stepped normalized collision energies, 20, 30, and 40% [52]. For HILIC-MS with the post-column addition of D<sub>2</sub>O, the tubing from the HILIC column and the infusion pump (Fusion 100, Chemyx, Stafford, TX, USA) introducing the D<sub>2</sub>O were coupled with a Tee unit before directing the flow into an ion source.

### 3.5. Data Processing

The HILIC-MS instrumental files from the metabolomic profiling were processed using MS-DIAL software v. 4.92, RIKEN, Yokohama, Japan [62] with the following parameters: (i) data collection: MS1 tolerance, 0.005; MS2 tolerance, 0.01; (ii) peak detection: minimum peak height, 20,000; mass slice width, 0.05; smoothing method, linear weighted moving average; smoothing level, 3; (iii) MS/MS identification settings: accurate mass tolerance (MS1), 0.005; accurate mass tolerance (MS2), 0.005; identification score cut-off, 80%; (iv) alignment: retention time tolerance, 0.05 min; MS1 tolerance, 0.01 Da; peak count filter, 5%; gap filling by compulsion, true. An in-house retention time– $m/z$  library and MS/MS libraries from various sources (NIST 23, MoNA, and LipidBlast) were used for the initial metabolite annotation. For data processing of the HILIC-MS data with the HDX experiments, MRMPROBS software 2.60, RIKEN [63] was used to obtain the peak heights of particular ions with the following parameters: smoothing method, linear weighted moving average; smoothing level, 3; minimum peak height, 100; retention time tolerance, 0.1 min; amplitude tolerance, 15%; minimum posterior, 70%; MS1 tolerance, 0.002. For structure elucidation, MS-FINDER software v. 3.60, RIKEN [27] was used with the following parameters: mass tolerance (MS1), 0.005 Da; mass tolerance (MS2), 0.005; relative abundance cut-off, 0.1%; LEWIS and SENIOR check, checked; isotopic ratio tolerance, 20%; element ratio check, common range (99.7%); element selection, O, N, P, S; tree depth, 2; local databases + MiNEs + PubChem, checked.

### 3.6. Statistical Analysis

The peak height intensities of N<sup>1</sup>-acetylspermidine from the HILIC-MS profiling were normalized to the amount (mg) and log<sub>10</sub>-transformed before processing using GraphPad Prism software v. 10.1, Boston, MA, USA to compare groups (two-way ANOVA, Tukey's);  $p < 0.05$  was considered significant.

#### 4. Conclusions

We evaluated the potential of LC-HDX-MS in untargeted metabolomics. The post-column addition of D<sub>2</sub>O in HILIC-MS exhibited limitations, particularly in achieving complete H/D exchange for the polar metabolites. However, the partial and full HILIC-HDX-MS setups, where both mobile phases included D<sub>2</sub>O, demonstrated improved performance with complete H/D exchange for the evaluated metabolites. Applying HILIC-HDX-MS to the unknown metabolite, N<sup>1</sup>-acetylspermidine, showcased its potential in reducing false positive annotations. LC-HDX-MS, combined with in silico fragmentation software, effectively reduces potential candidates for structure elucidation and has the potential for diverse untargeted metabolomics studies with specific applications in investigating diseases, circadian rhythms, nutrition, and other areas.

**Supplementary Materials:** The supporting information can be downloaded at <https://www.mdpi.com/article/10.3390/ijms25052899/s1>.

**Author Contributions:** Conceptualization, T.C.; methodology, T.C. and O.K.; software, T.C., M.N. and O.K.; validation, T.C.; formal analysis, T.C.; investigation, T.C., J.H., O.K., L.R.K., S.R., M.P., K.B. and V.H.; resources, T.C. and O.K.; data curation, T.C.; writing—original draft preparation, T.C.; writing—review and editing, T.C., O.F. and O.K.; visualization, T.C. and O.K.; supervision, T.C.; project administration, T.C.; funding acquisition, T.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Czech Science Foundation (20-21114S, 21-00477S) and the National Institute for Research for Metabolic and Cardiovascular Diseases (Programme EXCELES, ID Project No. LX22NPO5104) funded by the European Union—NextGenerationEU. Computational resources were provided by the e-INFRA CZ project (ID:90254), supported by the Ministry of Education, Youth and Sports of the Czech Republic. The data were acquired at the Metabolomics Core Facility at the Institute of Physiology of the Czech Academy of Sciences ([metabolomics.fgu.cas.cz](http://metabolomics.fgu.cas.cz), accessed on 25 February 2024).

**Institutional Review Board Statement:** The animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) and the Committee for Animal Protection of the Ministry of Agriculture of the Czech Republic (Approval Number: 81/2016) for the care and use of laboratory animals.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data are contained within this article and in the Supplementary Materials.

**Conflicts of Interest:** The authors declare no conflicts of interest.

#### References

1. Dettmer, K.; Aronov, P.A.; Hammock, B.D. Mass spectrometry-based metabolomics. *Mass Spectrom. Rev.* **2007**, *26*, 51–78. [[CrossRef](#)] [[PubMed](#)]
2. Lioupi, A.; Marinaki, M.; Virgiliou, C.; Begou, O.; Gika, H.; Wilson, I.; Theodoridis, G. Probing the polar metabolome by UHPLC-MS. *TrAC-Trend Anal. Chem.* **2023**, *161*, 117014. [[CrossRef](#)]
3. Feizi, N.; Hashemi-Nasab, F.S.; Golpelichi, F.; Saburouh, N.; Parastar, H. Recent trends in application of chemometric methods for GC-MS and GCxGC-MS-based metabolomic studies. *TrAC-Trend Anal. Chem.* **2021**, *138*, 116239. [[CrossRef](#)]
4. Rampler, E.; El Abiead, Y.; Schoeny, H.; Ruzs, M.; Hildebrand, F.; Fitz, V.; Koellensperger, G. Recurrent topics in mass spectrometry-based metabolomics and lipidomics—standardization, coverage, and throughput. *Anal. Chem.* **2021**, *93*, 519–545. [[CrossRef](#)] [[PubMed](#)]
5. Soga, T. Advances in capillary electrophoresis mass spectrometry for metabolomics. *TrAC-Trend Anal. Chem.* **2023**, *158*, 116883. [[CrossRef](#)]
6. Rhee, E.P.; Waikar, S.S.; Rebholz, C.M.; Zheng, Z.H.; Perichon, R.; Clish, C.B.; Evans, A.M.; Avila, J.; Denburg, M.R.; Anderson, A.H.; et al. Variability of two metabolomic platforms in CKD. *Clin. J. Am. Soc. Nephrol.* **2019**, *14*, 40–48. [[CrossRef](#)]
7. Dyar, K.A.; Lutter, D.; Artati, A.; Ceglia, N.J.; Liu, Y.; Armenta, D.; Jastroch, M.; Schneider, S.; de Mateo, S.; Cervantes, M.; et al. Atlas of circadian metabolism reveals system-wide coordination and communication between clocks. *Cell* **2018**, *174*, 1571–1585. [[CrossRef](#)]
8. Abbondante, S.; Eckel-Mahan, K.L.; Ceglia, N.J.; Baldi, P.; Sassone-Corsi, P. Comparative circadian metabolomics reveal differential effects of nutritional challenge in the serum and liver. *J. Biol. Chem.* **2016**, *291*, 2812–2828. [[CrossRef](#)]



9. Rakusanova, S.; Fiehn, O.; Cajka, T. Toward building mass spectrometry-based metabolomics and lipidomics atlases for biological and clinical research. *TrAC-Trend Anal. Chem.* **2023**, *158*, 116825. [[CrossRef](#)]
10. da Silva, R.R.; Dorrestein, P.C.; Quinn, R.A. Illuminating the dark matter in metabolomics. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 12549–12550. [[CrossRef](#)] [[PubMed](#)]
11. de Jonge, N.F.; Mildau, K.; Meijer, D.; Louwen, J.J.R.; Bueschl, C.; Huber, F.; van der Hooft, J.J.J. Good practices and recommendations for using and benchmarking computational metabolomics metabolite annotation tools. *Metabolomics* **2022**, *18*, 103. [[CrossRef](#)]
12. Minami, Y.; Kasukawa, T.; Kakazu, Y.; Iigo, M.; Sugimoto, M.; Ikeda, S.; Yasui, A.; van der Horst, G.T.J.; Soga, T.; Ueda, H.R. Measurement of internal body time by blood metabolomics. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 9890–9895. [[CrossRef](#)]
13. Mahieu, N.G.; Patti, G.J. Systems-level annotation of a metabolomics data set reduces 25 000 features to fewer than 1000 unique metabolites. *Anal. Chem.* **2017**, *89*, 10397–10406. [[CrossRef](#)]
14. Pinto, R.C.; Karaman, I.; Lewis, M.R.; Hällqvist, J.; Kaluarachchi, M.; Graça, G.; Chekmeneva, E.; Durainayagam, B.; Ghanbari, M.; Ikram, M.A.; et al. Finding correspondence between metabolomic features in untargeted liquid chromatography-mass spectrometry metabolomics datasets. *Anal. Chem.* **2022**, *94*, 5493–5503. [[CrossRef](#)]
15. Kasukawa, T.; Sugimoto, M.; Hida, A.; Minami, Y.; Mori, M.; Honma, S.; Honma, K.; Mishima, K.; Soga, T.; Ueda, H.R. Human blood metabolite timetable indicates internal body time. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 15036–15041. [[CrossRef](#)] [[PubMed](#)]
16. Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; Dugar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.M.; et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* **2011**, *472*, 57–63. [[CrossRef](#)]
17. Chen, Z.Z.; Gerszten, R.E. Metabolomics and proteomics in type 2 diabetes. *Circ. Res.* **2020**, *126*, 1613–1627. [[CrossRef](#)]
18. Wikoff, W.R.; Hanash, S.; DeFelice, B.; Miyamoto, S.; Barnett, M.; Zhao, Y.; Goodman, G.; Feng, Z.; Gandara, D.; Fiehn, O.; et al. Diacetylspermine is a novel prediagnostic serum biomarker for non-small-cell lung cancer and has additive performance with pro-surfactant protein B. *J. Clin. Oncol.* **2015**, *33*, 3880–3886. [[CrossRef](#)] [[PubMed](#)]
19. Low, D.Y.; Lefvre-Arbogast, S.; Gonzalez-Domnguez, R.; Urpi-Sarda, M.; Micheau, P.; Petera, M.; Centeno, D.; Durand, S.; Pujos-Guillot, E.; Korosi, A.; et al. Diet-related metabolites associated with cognitive decline revealed by untargeted metabolomics in a prospective cohort. *Mol. Nutr. Food Res.* **2019**, *63*, 1900177. [[CrossRef](#)] [[PubMed](#)]
20. Qiu, S.; Cai, Y.; Yao, H.; Lin, C.S.; Xie, Y.Q.; Tang, S.Q.; Zhang, A.H. Small molecule metabolites: Discovery of biomarkers and therapeutic targets. *Signal Transduct. Target. Ther.* **2023**, *8*, 132. [[CrossRef](#)]
21. Cai, Y.P.; Zhou, Z.W.; Zhu, Z.J. Advanced analytical and informatic strategies for metabolite annotation in untargeted metabolomics. *TrAC-Trend Anal. Chem.* **2023**, *158*, 116903. [[CrossRef](#)]
22. Zhu, Z.J.; Schultz, A.W.; Wang, J.H.; Johnson, C.H.; Yannone, S.M.; Patti, G.J.; Siuzdak, G. Liquid chromatography quadrupole time-of-flight mass spectrometry characterization of metabolites guided by the METLIN database. *Nat. Protoc.* **2013**, *8*, 451–460. [[CrossRef](#)] [[PubMed](#)]
23. Bittremieux, W.; Wang, M.X.; Dorrestein, P.C. The critical role that spectral libraries play in capturing the metabolomics community knowledge. *Metabolomics* **2022**, *18*, 94. [[CrossRef](#)] [[PubMed](#)]
24. Chaleckis, R.; Meister, I.; Zhang, P.; Wheelock, C.E. Challenges, progress and promises of metabolite annotation for LC-MS-based metabolomics. *Curr. Opin. Biotechnol.* **2019**, *55*, 44–50. [[CrossRef](#)] [[PubMed](#)]
25. Alseekh, S.; Aharoni, A.; Brotman, Y.; Contrepolis, K.; D’Auria, J.; Ewald, J.; Ewald, J.C.; Fraser, P.D.; Giavalisco, P.; Hall, R.D.; et al. Mass spectrometry-based metabolomics: A guide for annotation, quantification and best reporting practices. *Nat. Methods* **2021**, *18*, 747–756. [[CrossRef](#)]
26. Purwaha, P.; Silva, L.P.; Hawke, D.H.; Weinstein, J.N.; Lorenzi, P.L. An artifact in LC-MS/MS measurement of glutamine and glutamic acid: In-source cyclization to pyroglutamic acid. *Anal. Chem.* **2014**, *86*, 5633–5637. [[CrossRef](#)]
27. Tsugawa, H.; Kind, T.; Nakabayashi, R.; Yukihira, D.; Tanaka, W.; Cajka, T.; Saito, K.; Fiehn, O.; Arita, M. Hydrogen rearrangement rules: Computational MS/MS fragmentation and structure elucidation using MS-FINDER software. *Anal. Chem.* **2016**, *88*, 7946–7958. [[CrossRef](#)]
28. Krettler, C.A.; Thallinger, G.G. A map of mass spectrometry-based fragmentation prediction and compound identification in metabolomics. *Brief. Bioinform.* **2021**, *22*, bbab073. [[CrossRef](#)]
29. Duhrkop, K.; Shen, H.B.; Meusel, M.; Rousu, J.; Bocker, S. Searching molecular structure databases with tandem mass spectra using CSI:FingerID. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 12580–12585. [[CrossRef](#)]
30. Allen, F.; Pon, A.; Wilson, M.; Greiner, R.; Wishart, D. CFM-ID: A web server for annotation, spectrum prediction and metabolite identification from tandem mass spectra. *Nucleic Acids Res.* **2014**, *42*, W94–W99. [[CrossRef](#)]
31. Wang, Y.F.; Kora, G.; Bowen, B.P.; Pan, C.L. MIDAS: A database-searching algorithm for metabolite identification in metabolomics. *Anal. Chem.* **2014**, *86*, 9496–9503. [[CrossRef](#)]
32. Ruttkies, C.; Schymanski, E.L.; Wolf, S.; Hollender, J.; Neumann, S. MetFrag relaunched: Incorporating strategies beyond fragmentation. *J. Cheminform.* **2016**, *8*, 3. [[CrossRef](#)]
33. Liu, D.Q.; Wu, L.M.; Sun, M.J.; MacGregor, P.A. On-line H/D exchange LC-MS strategy for structural elucidation of pharmaceutical impurities. *J. Pharmaceut. Biomed.* **2007**, *44*, 320–329. [[CrossRef](#)]
34. Fischer, C.R.; Wilmes, P.; Bowen, B.P.; Northen, T.R.; Banfield, J.F. Deuterium-exchange metabolomics identifies N-methyl lyso phosphatidylethanolamines as abundant lipids in acidophilic mixed microbial communities. *Metabolomics* **2012**, *8*, 566–578. [[CrossRef](#)]
35. Lam, W.; Ramanathan, R. In electrospray ionization source hydrogen/deuterium exchange LC-MS and LC-MS/MS for characterization of metabolites. *J. Am. Soc. Mass Spectr.* **2002**, *13*, 345–353. [[CrossRef](#)]



36. Liu, D.Q.; Hop, C.E.C.A. Strategies for characterization of drug metabolites using liquid chromatography-tandem mass spectrometry in conjunction with chemical derivatization and on-line H/D exchange approaches. *J. Pharm. Biomed. Anal.* **2005**, *37*, 1–18. [[CrossRef](#)]
37. Shah, R.P.; Garg, A.; Putlur, S.P.; Wagh, S.; Kumar, V.; Rao, V.; Singh, S.; Mandlekar, S.; Desikan, S. Practical and economical implementation of online H/D exchange in LC-MS. *Anal. Chem.* **2013**, *85*, 10904–10912. [[CrossRef](#)] [[PubMed](#)]
38. Damont, A.; Legrand, A.; Cao, C.Q.; Fenaille, F.; Tabet, J.C. Hydrogen/deuterium exchange mass spectrometry in the world of small molecules. *Mass Spectrom. Rev.* **2023**, *42*, 1300–1331. [[CrossRef](#)] [[PubMed](#)]
39. Pfeifer, T.; Tuerk, J.; Fuchs, R. Structural characterization of sulfadiazine metabolites using H/D exchange combined with various MS/MS experiments. *J. Am. Soc. Mass Spectr.* **2005**, *16*, 1687–1694. [[CrossRef](#)] [[PubMed](#)]
40. Novak, T.J.; Helmy, R.; Santos, I. Liquid chromatography-mass spectrometry using the hydrogen/deuterium exchange reaction as a tool for impurity identification in pharmaceutical process development. *J. Chromatogr. B* **2005**, *825*, 161–168. [[CrossRef](#)] [[PubMed](#)]
41. Muz, M.; Krauss, M.; Kutsarova, S.; Schulze, T.; Brack, W. Mutagenicity in surface waters: Synergistic effects of carboline alkaloids and aromatic amines. *Environ. Sci. Technol.* **2017**, *51*, 1830–1839. [[CrossRef](#)]
42. Acter, T.; Kim, D.; Ahmed, A.; Ha, J.H.; Kim, S. Application of atmospheric pressure photoionization H/D-exchange mass spectrometry for speciation of sulfur-containing compounds. *J. Am. Soc. Mass Spectr.* **2017**, *28*, 1687–1695. [[CrossRef](#)]
43. Zhrebker, A.; Kostyukevich, Y.; Kononikhin, A.; Roznyatovsky, V.A.; Popov, I.; Grishin, Y.K.; Perminova, I.V.; Nikolaev, E. High desolvation temperature facilitates the ESI-source H/D exchange at non-labile sites of hydroxybenzoic acids and aromatic amino acids. *Analyst* **2016**, *141*, 2426–2434. [[CrossRef](#)]
44. Kostyukevich, Y.; Acter, T.; Zhrebker, A.; Ahmed, A.; Kim, S.; Nikolaev, E. Hydrogen/deuterium exchange in mass spectrometry. *Mass Spectrom. Rev.* **2018**, *37*, 811–853. [[CrossRef](#)]
45. De Vijlder, T.; Valkenburg, D.; Lemiere, F.; Romijn, E.P.; Laukens, K.; Cuyckens, F. A tutorial in small molecule identification via electrospray ionization-mass spectrometry: The practical art of structural elucidation. *Mass Spectrom. Rev.* **2018**, *37*, 607–629. [[CrossRef](#)] [[PubMed](#)]
46. Ruttkies, C.; Schymanski, E.L.; Strehmel, N.; Hollender, J.; Neumann, S.; Williams, A.J.; Krauss, M. Supporting non-target identification by adding hydrogen deuterium exchange MS/MS capabilities to MetFrag. *Anal. Bioanal. Chem.* **2019**, *411*, 4683–4700. [[CrossRef](#)] [[PubMed](#)]
47. Zhang, Q.B.; Ford, L.A.; Evans, A.M.; Toal, D.R. Structure elucidation of metabolite x17299 by interpretation of mass spectrometric data. *Metabolomics* **2017**, *13*, 92. [[CrossRef](#)] [[PubMed](#)]
48. Zhang, Q.B.; Ford, L.A.; Evans, A.M.; Toal, D.R. Identification of an endogenous organosulfur metabolite by interpretation of mass spectrometric data. *Org. Lett.* **2018**, *20*, 2100–2103. [[CrossRef](#)] [[PubMed](#)]
49. Wei, Y.Y.; Sun, Y.; Jia, S.L.; Yan, P.; Xiong, C.M.; Qi, M.L.; Wang, C.X.; Du, Z.F.; Jiang, H.L. Identification of endogenous carbonyl steroids in human serum by chemical derivatization, hydrogen/deuterium exchange mass spectrometry and the quantitative structure-retention relationship. *J. Chromatogr. B* **2023**, *1226*, 123776. [[CrossRef](#)] [[PubMed](#)]
50. Kostyukevich, Y.; Vladimirov, G.; Stekolschikova, E.; Ivanov, D.; Yablokov, A.; Zhrebker, A.; Sosnin, S.; Orlov, A.; Fedoroy, M.; Khaitovich, P.; et al. Hydrogen/deuterium exchange aiding compound identification for LC-MS and MALDI imaging lipidomics. *Anal. Chem.* **2019**, *91*, 13465–13474. [[CrossRef](#)] [[PubMed](#)]
51. Strehmel, N.; Böttcher, C.; Schmidt, S.; Scheel, D. Profiling of secondary metabolites in root exudates of *Arabidopsis thaliana*. *Phytochemistry* **2014**, *108*, 35–46. [[CrossRef](#)]
52. Cajka, T.; Hricko, J.; Rudl Kulhava, L.; Paucova, M.; Novakova, M.; Kuda, O. Optimization of mobile phase modifiers for fast LC-MS-based untargeted metabolomics and lipidomics. *Int. J. Mol. Sci.* **2023**, *24*, 1987. [[CrossRef](#)] [[PubMed](#)]
53. Hamuro, Y. Tutorial: Chemistry of hydrogen/deuterium exchange mass spectrometry. *J. Am. Soc. Mass Spectrom.* **2021**, *32*, 133–151. [[CrossRef](#)]
54. Ball, D.; Nguyen, T.; Zhang, N.F.; D’Arcy, S. Using hydrogen-deuterium exchange mass spectrometry to characterize Mtr4 interactions with RNA. *Method Enzymol.* **2022**, *673*, 475–516.
55. Hatvany, J.B.; Liyanage, O.T.; Gallagher, E.S. Effect of pH on in-electrospray hydrogen/deuterium exchange of carbohydrates and peptides. *J. Am. Soc. Mass Spectrom.* **2024**; online ahead of print. [[CrossRef](#)] [[PubMed](#)]
56. Castillo, P.; Kuda, O.; Kopecky, J.; Pomar, C.A.; Palou, A.; Palou, M.; Picó, C. Reverting to a healthy diet during lactation normalizes maternal milk lipid content of diet-induced obese rats and prevents early alterations in the plasma lipidome of the offspring. *Mol. Nutr. Food Res.* **2022**, *66*, 2200204. [[CrossRef](#)] [[PubMed](#)]
57. Greiner, P.; Houdek, P.; Sládek, M.; Sumová, A. Early rhythmicity in the fetal suprachiasmatic nuclei in response to maternal signals detected by omics approach. *PLoS Biol.* **2022**, *20*, e3001637. [[CrossRef](#)]
58. Benova, A.; Ferencakova, M.; Bardova, K.; Funda, J.; Prochazka, J.; Spoutil, F.; Cajka, T.; Dzubanová, M.; Balcaen, T.; Kerckhofs, G.; et al. Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones. *Mol. Metab.* **2022**, *65*, 101598. [[CrossRef](#)]
59. Janovska, P.; Melenovsky, V.; Svobodova, M.; Havlenova, T.; Kratochvilova, H.; Haluzik, M.; Hoskova, E.; Pelikanova, T.; Kautzner, J.; Monzo, L.; et al. Dysregulation of epicardial adipose tissue in cachexia due to heart failure: The role of natriuretic peptides and cardiolipin. *J. Cachexia Sarcopenia Muscle* **2020**, *11*, 1614–1627. [[CrossRef](#)]
60. Grazul, H.; Kanda, L.L.; Gondek, D. Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice. *Gut Microbes* **2016**, *7*, 101–114. [[CrossRef](#)]

61. Hricko, J.; Kulhava, L.R.; Paucova, M.; Novakova, M.; Kuda, O.; Fiehn, O.; Cajka, T. Short-term stability of serum and liver extracts for untargeted metabolomics and lipidomics. *Antioxidants* **2023**, *12*, 986. [[CrossRef](#)] [[PubMed](#)]
62. Tsugawa, H.; Ikeda, K.; Takahashi, M.; Satoh, A.; Mori, Y.; Uchino, H.; Okahashi, N.; Yamada, Y.; Tada, I.; Bonini, P.; et al. A lipidome atlas in MS-DIAL 4. *Nat. Biotechnol.* **2020**, *38*, 1159–1163. [[CrossRef](#)] [[PubMed](#)]
63. Tsugawa, H.; Arita, M.; Kanazawa, M.; Ogiwara, A.; Bamba, T.; Fukusaki, E. MRMPROBS: A data assessment and metabolite identification tool for large-scale multiple reaction monitoring based widely targeted metabolomics. *Anal. Chem.* **2013**, *85*, 5191–5199. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.